A Predictive Model Based on Bi-parametric Magnetic Resonance Imaging and Clinical Parameters for Clinically Significant Prostate Cancer in the Korean Population.


Journal

Cancer research and treatment
ISSN: 2005-9256
Titre abrégé: Cancer Res Treat
Pays: Korea (South)
ID NLM: 101155137

Informations de publication

Date de publication:
Oct 2021
Historique:
received: 18 10 2020
accepted: 31 12 2020
pubmed: 11 1 2021
medline: 8 2 2022
entrez: 10 1 2021
Statut: ppublish

Résumé

This study aimed to develop and validate a predictive model for the assessment of clinically significant prostate cancer (csPCa) in men, prior to prostate biopsies, based on bi-parametric magnetic resonance imaging (bpMRI) and clinical parameters. We retrospectively analyzed 300 men with clinical suspicion of prostate cancer (prostate-specific antigen [PSA] ≥ 4.0 ng/mL and/or abnormal findings in a digital rectal examination), who underwent bpMRI-ultrasound fusion transperineal targeted and systematic biopsies in the same session, at a Korean university hospital. Predictive models, based on Prostate Imaging Reporting and Data Systems scores of bpMRI and clinical parameters, were developed to detect csPCa (intermediate/high grade [Gleason score ≥ 3+4]) and compared by analyzing the areas under the curves and decision curves. A predictive model defined by the combination of bpMRI and clinical parameters (age, PSA density) showed high discriminatory power (area under the curve, 0.861) and resulted in a significant net benefit on decision curve analysis. Applying a probability threshold of 7.5%, 21.6% of men could avoid unnecessary prostate biopsy, while only 1.0% of significant prostate cancers were missed. This predictive model provided a reliable and measurable means of risk stratification of csPCa, with high discriminatory power and great net benefit. It could be a useful tool for clinical decision-making prior to prostate biopsies.

Identifiants

pubmed: 33421975
pii: crt.2020.1068
doi: 10.4143/crt.2020.1068
pmc: PMC8524004
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1148-1155

Subventions

Organisme : College of Medicine, Korea University

Références

Prostate Cancer Prostatic Dis. 2018 Apr;21(1):57-63
pubmed: 29259293
Lancet. 2017 Feb 25;389(10071):815-822
pubmed: 28110982
Prostate Cancer Prostatic Dis. 2020 Mar;23(1):88-93
pubmed: 31239513
Cancer Res Treat. 2020 Jul;52(3):714-721
pubmed: 32054151
Eur Urol Oncol. 2019 Sep;2(5):490-496
pubmed: 31412016
JAMA Oncol. 2018 May 1;4(5):678-685
pubmed: 29470570
BJU Int. 2015 Mar;115(3):381-8
pubmed: 24447678
Radiology. 2017 Nov;285(2):493-505
pubmed: 28727544
Urology. 2002 Jun;59(6):797-802
pubmed: 12031356
JAMA Netw Open. 2018 Jun 1;1(2):e180219
pubmed: 30646066
Eur Urol. 2012 Apr;61(4):652-61
pubmed: 22134009
Eur Radiol. 2020 Oct;30(10):5404-5416
pubmed: 32424596
Urology. 2006 Apr;67(4):762-8
pubmed: 16600352
Crit Rev Oncol Hematol. 2017 Dec;120:180-193
pubmed: 29198331
Eur Urol. 2019 Apr;75(4):570-578
pubmed: 30477981
Eur Urol. 2010 Jan;57(1):79-85
pubmed: 19733959
Eur Urol. 2019 Feb;75(2):310-318
pubmed: 30082150
BJU Int. 2017 Dec;120(6):774-781
pubmed: 28207981
J Magn Reson Imaging. 2017 Oct;46(4):1089-1095
pubmed: 28165653
Int J Mol Sci. 2019 Apr 02;20(7):
pubmed: 30986955
Eur Urol. 2017 Dec;72(6):888-896
pubmed: 28400169
Cancer Treat Res. 2018;175:55-86
pubmed: 30168117
Prostate Cancer Prostatic Dis. 2019 Mar;22(1):101-109
pubmed: 30127462
Eur Urol. 2018 Apr;73(4):572-582
pubmed: 29129398
BJU Int. 2020 Mar;125(3):407-416
pubmed: 31758738
BMJ. 2016 Jan 25;352:i6
pubmed: 26810254
Prostate Cancer Prostatic Dis. 2019 May;22(2):331-336
pubmed: 30413806
Transl Androl Urol. 2018 Feb;7(1):18-26
pubmed: 29594016

Auteurs

Tae Il Noh (TI)

Department of Urology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.

Chang Wan Hyun (CW)

Department of Urology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.

Ha Eun Kang (HE)

Department of Urology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.

Hyun Jung Jin (HJ)

Department of Urology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.

Jong Hyun Tae (JH)

Department of Urology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.

Ji Sung Shim (JS)

Department of Urology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.

Sung Gu Kang (SG)

Department of Urology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.

Deuk Jae Sung (DJ)

Department of Urology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.
Department of Radiology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.

Jun Cheon (J)

Department of Urology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.

Jeong Gu Lee (JG)

Department of Urology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.

Seok Ho Kang (SH)

Department of Urology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH